What is the outcome of Door-to-needle Time within 60minutes for acute ischemic stroke patients treat with t-PA? Chi-Ching Chen 1, Hui-Fen Huang 1, Yu-Ling.

Slides:



Advertisements
Similar presentations
JCAHO EXPECTATIONS FOR PRIMARY STROKE CENTER
Advertisements

© 2010, American Heart Association. All rights reserved. Hospital Performance Recognition with the Get with the Guidelines Program and Mortality for Acute.
3/28/2017© 2009, American Heart Association. All rights reserved.
The Golden Hour and Acute Brain Ischemia: Presenting Features and Lytic Therapy in Over 30,000 Patients Arriving within 60 Minutes of Onset at GWTG-S.
Stroke: A process improvement project Niloufar Hadidi, APRN, BC Neuroscience Clinical Nurse Specialist PhD student, University of Minnesota School of Nursing.
Risks of Intracranial Hemorrhage among Patients with Acute Ischemic Stroke Receiving Warfarin and Treated with Intravenous Tissue Plasminogen Activator.
Accomplishments in Stroke Care
DISCLOSURE INFORMATION: Target: Stroke is an initiative provided by the American Heart Association/American Stroke Association. The University of California,
Beyond the Basics of Stroke Evaluation
DISCLOSURE INFORMATION (relative only): Eric D. Peterson, PI of the AHA GWTG Data Analysis Center; Lee H. Schwamm, Chair of the AHA National Steering Committee.
Thrombolysis for stroke in older people.
B.A.P.E.T Brain Attack Protocol & Emergency Treatment By: Nicole Florentine, Christina Lauderman Erin Patrick, & Kara Sharp.
TPA… SMART or not SMART? That is the Question. Sarah Parker, MD.
G.N. Dalekos3, M. Elisaf2, A.I. Hatzitolios1
Disclosures: Maximo C. Kiok, M.D. Medical Director of Stroke Program Trinity Health System.
Target: Stroke Building on Success A national quality improvement initiative of the American Heart Association/American Stroke Association to improve.
Emily O’Brien, MSPH Predoctoral Trainee February 16, 2010 The North Carolina Stroke Care Collaborative Clinical Outcomes among Stroke Patients Receiving.
“Influence of Stroke Subtype on Quality of Care in The Get With The Guidelines-Stroke Program” Eric E. Smith, MD, MPH; Li Liang PhD; Adrian F Hernandez,
Disclosures The Get With The Guidelines®–Stroke (GWTG-Stroke) program is provided by the American Heart Association/American Stroke Association. The GWTG-
Dr Amer Jafar. Early Dementia After First-Ever Stroke From 1985 to 2008, overall first-ever strokes occurring within the population of the city of Dijon,
“ Age-Related Differences in Characteristics, Performance Measures, Treatment Trends, and Outcomes in Patients with Ischemic Stroke ” Gregg C. Fonarow,
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
Brain Single-Photon Emission CT With HMPAO and Safety of Thrombolytic Therapy in Acute Ischemic Stroke Proceedings of the Meeting of the SPECT Safe Thrombolysis.
Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,
TPA in Acute Ischemic Stroke: The NINDS Reanalysis & Meta-analysis Data Sidney Starkman, MD, FACEP.
T-PA in Treatment of Acute Stroke: What We Know From NINDS 2004 vs 2000 Sidney Starkman, MD Departments of Emergency Medicine and Neurology, UCLA UCLA.
Healthcare Facilities Accreditation Program (HFAP) Primary Stroke Certification Troy Repuszka, RN, BScN July 16, 2009.
FERNE/MEMC Session: Treating Ischemic Stroke in the 3 – 4
Canadian Diabetes Association Clinical Practice Guidelines Management of Stroke in Diabetes Chapter 27 Michael Sharma, Gord Gubitz.
Quality of Care and Outcomes in Patients with Diabetes Hospitalized with Ischemic Stroke Findings From Get With The Guidelines-Stroke Reeves MJ; Vaidya.
‘STROKE’ September 2010 Dr. Amer Jafar.
Schwamm et al. Circulation epub April 6Schwamm et al. Race/Ethnicity, Quality of Care, and Outcomes in Ischemic Stroke Lee H. Schwamm, MD; Mathew.
1 EFFECT STUDY 2 EFFECT STUDY  Set national cardiac care benchmarks for hospitals to work towards 
Original Article Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke Werner Hacke, M.D., Markku Kaste, M.D., Erich Bluhmki, Ph.D., Miroslav.
10 May 2005 CASES - Original article available at CASES (Canadian Alteplase for Stroke Effectiveness Study) The CASES Investigators.
Thrombolysis in acute ischaemic stroke – Updated Cochrane Thrombolysis metaanalysis JM Wardlaw, V Murray, PAG Sandercock University of Edinburgh and Karolinska.
The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement Thomas.
Tissue Plasminogen Activator for Acute Ischemic Stroke National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
Evidence in the ED Byron Drumheller, MD Penn Emergency Medicine.
Overview of new acute stroke trials Shawna Cutting, MD, MS Rush University Medical Center June 9, 2015.
Update in ESC: Dabigatran among OAC
DR AMER JAFAR ‘STROKE’ October Ethnicity and recurrence of stroke Population-based study Compared poststroke recurrence and survival in Mexican.
Long-term clinical outcome following emergency MR-based reperfusion therapy for acute middle cerebral artery occlusion Department of Stroke Treatment,
Kim, Sun-Yong, M.D. Department of Radiology Ajou University Hospital, Suwon, Korea AGGRESIVE MECHANICAL CLOT DISRUPTION FOR ACUTE ISCHEMIC STROKE WITH.
“Door to Needle (DTN) Time in Stroke Thrombolysis” Audit Care of the Elderly Department Dr Nikoletta Petrou, Foundation Year 1 Doctor Dr Prasanna Aghoram,
Sanaz Sakiani, MD Endocrinology Fellow Journal Club
Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Mechanical Thrombectomy for Acute Ischemic Stroke:
Identifying Actionable Post-Acute Stroke Concerns:
Outcomes of thrombolysis treatment in patients with dementia and acute ischemic stroke A longitudinal cohort study from SveDem and Riksstroke, Swedish.
Treating Acute Ischemic Stroke, Can We Open Up the Time Window?
Multimodal Predictors of Massive Ischemic Stroke & Favourable Outcome.
Table 1: Table 2: Non Therapeutic Angiograms in Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment Does not Adversely Affect Patient.
Direct catheter-based thrombectomy in acute ischemic stroke
Thrombectomy in Acute Stroke
Acute Stroke Therapy with IV Thrombolysis Lawrence R. Wechsler, M.D.
First Stroke Unit in Al Ain: Five Years Experience
CAS in acute stroke C. Roth‡, P. Papanagiotou‡, A. M. Politi‡, K. W. Reith‡ Department of diagnostic.
Copyright © 2010 American Medical Association. All rights reserved.
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
STROKE Afifah Machlaurin.
Haris Kamal, MD; Ashkan Mowla, MD,FAHA ; Navdeep S
Mechanical thrombectomy
Target: Stroke Honor Roll
Welcome to today’s webinar
Stroke Early Supported Discharge Team Service Evaluation
Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?
Modified Rankin score 0-2
Extended Window Thrombectomy
Three outcome measures from the NINDS tPA trial
Jennifer E. Fugate, DO, Alejandro A. Rabinstein, MD 
Presentation transcript:

What is the outcome of Door-to-needle Time within 60minutes for acute ischemic stroke patients treat with t-PA? Chi-Ching Chen 1, Hui-Fen Huang 1, Yu-Ling Hung 2, Yu-Yun Hsu 4, Han-Jung Lee 4, Chun-Hung Chen 3,4 1 Department of Nursing, Kaohsiung medical University Hospital, Kaohsiung medical University, Kaohsiung, Taiwan 2 Department of Nursing, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung medical University, Kaohsiung, Taiwan 3 Department of Neurology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung, Taiwan 4 Department of Neurology, Kaohsiung medical University Hospital, Kaohsiung medical University, Kaohsiung, Taiwan Table2. Clinical outcome between DTN with/without 60 minutes of acute ischemic stroke patients DTN(n) ≦ 1hr(n=40) > 1hr(n=43) P-value O to N(min) 114.7± ± DTN(min) 45.28± ± △ NIHSS 5.68± ± Days(admission) 15.83± ± ICH SICH Mortality Spend(NT) ± ± post1mRS post3mRS post6mRS O to N: onset-to-needle time SICH: symptomatic intra-cranial hemorrhage Background The good outcome of intravenous tissue-type plasminogen activator (t-PA) in acute ischemic stroke (AIS) patients are time-dependent. Recent many stroke guidelines recommend door-to-needle time (DTN) must be within 60 minutes for AIS patients treated with t-PA. The aim of our study was to evaluate the clinical outcome associated with DTN time ≦ 60 minutes. Methods During 4-year study period (2010~2013), we enrolled 69 acute ischemic stroke patients treated with intravenous tissue plasminogen activator (iv-tPA) within 3 hours after symptom onset. Thirty-four patients administrated iv-tPA within 1 hour, and the other (35 patients) were treated more than 1 hour. Data collected were patients’ characteristics, tPA dosage, time points (stroke symptom onset, presentation to ED, neuroimaging and thrombolysis), clinical outcome (90 th days modified Rankin Scale (mRS), change of National Institute of Health Stroke Scale (NIHSS) at discharge, intracerebral hemorrhage (ICH) and death during admission), length of admission (LOA), and hospital cost. admission). Results Among 83 patients, only 40 (48.2%) DTN time was ≦ 60 minutes. Patient demographic factors, characteristics, clinical outcome and 30, 90,180-day mRS were no significant different when compared with and without DTN times ≦ 60 minutes. The mean time of DTN ≦ 60 minutes group was shorter (45.28 ±10.22 vs 91.09±22.98, p < ), and the same result was found in mean time of onset-to-needle (OTN) (114.7±37.74 vs ±29.84, p=0.001). Conclusions Despite the guidelines recommend the rate of DTN time ≦ 60 minutes must be 50% at least in AIS patient treat with t- PA. It only near one-half of patient achieved this target over the past 4 years in our hospital. Our data cannot reveal significant good outcome for AIS patient treat with t-PA within 60 minutes. But, it is only a preliminary result of our study, we need more case number and longer period of observation time can prove the benefit of shortening DTN time for AIS patients. Reference 1. Gregg C. Fonarow, Eric E. Smith, Jeffrey L. Saver, et. Timeliness of Tissue- Type Plasminogen Activator Therapy in Acute Ischemic Stroke Patient Characteristics, Hospital Factors, and Outcomes Associated With Door-to-Needle Times Within 60 Minutes. Circulation. 2011;123: Greg g C. Fonarow, Xin Zhao, Eric E. Smith, et. Door-to-Needle Times for Tissue Plasminogen Activator Administration and Clinical Outcomes in Acute Ischemic Stroke Before and After a Quality Improvement Initiative. JA M A. 2014;311(16): Jauch EC, Saver JL, Adams HP, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American. Stroke Association. Stroke 2013:1–8 Figure 1 Post-stroke 1mRS between DTN with/without 60 minutes Figure 2 Post-stroke 3mRS between DTN with/without 60 minutes Figure 3 Post-stroke 6mRS between DTN with/without 60 minutes Table 1. Characteristics of all acute ischemic stroke patients DTN(n) ≦ 1hr(n=40) > 1hr(n=43) P-value Age(year) 62.35± ± Gender(F/M)15/2516/ Dosage mg/kg 0.82± ± Hypertension Diabetes Previons CVA / TIA Dyalipidemia Atrial fibrillation Heart disease O to ER(min)65.25± ± NIHSS (Admission) 13.65± ± DTN: door-to-needle time O to ER: onset-to-ER NIHSS: National Institute of Health Stroke Scale